Novartis has published results from a clinical trial of Pear Therapeutics' new digital therapeutic for schizophrenia, and the results don't paint a rosy picture.
The single-blinded 112-person trial found no difference between the Pear app and a placebo app in any outcome measure, including the primary outcome measure of reducing schizophrenia symptoms. However, the trial did further establish the...
Editor's note: This story has been updated with quotes and additional information from Mahana's CEO and cofounder.
The FDA has granted a De Novo clearance to San Francisco-based Mahana Therapeutics' Parallel, a prescription digital therapeutic for patients with irritable bowel syndrome (IBS) that delivers cognitive behavioral therapy (CBT).
The agency made its decision on November 25, according...
Prescription digital therapeutics startup Pear Therapeutics announced an $80 million Series D round this morning headed by SoftBank Vision Fund 2.
The raise included funds from new backers Forth Management, Pilot House, Sarissa Capital, Shanda Group and QUAD Investment Management, as well as from returning investors Temasek, 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis,...
Digital therapeutics firm Kaia Health is partnering with Italian pharma firm Chiesi Group to commercialise its chronic obstructive pulmonary disease (COPD) rehabilitation app in Europe.
The Kaia COPD solution consists of a mobile app and an interface for motivational support that aims to deliver a personalised pulmonary rehabilitation experience through education, daily training sessions and...
Considered one of the most innovative areas within digital health, the prescription digital therapeutics (PDT) ecosystem has experienced an accelerated period of progress over the past two years. A prescription digital therapeutic is a prescription-only software that delivers evidence-based therapeutic intervention(s) to prevent, manage or treat a medical disorder or disease.
While considerable...
Pear Therapeutics announced today the availability of its prescription digital therapeutic for chronic insomnia in adults over the age of 22, called Somryst.
Somryst uses cognitive behavioral therapy for insomnia (CBTi) to train the brain and body to sleep. Over the course of the patient’s program, the therapy guides them through lessons and challenges, including algorithm-driven sleep...
A recently published review of real-world claims data suggests that opioid use disorder patients prescribed Pear Therapeutics' reSET-O digital therapeutic, alongside pharmacotherapy, had fewer clinical encounters and subsequently decreased medical costs over a six-month period.
The study was funded by Pear, coauthored by a Pear employee and published in the journal Expert Review of...
A study from UK-based analyst house, Juniper Research has found that the number of people using digital therapeutics and wellness apps will grow from 627 million in 2020 to more than 1.4 billion in 2025.
This follows regulators responding to COVID-19 by loosening rules that had previously delayed the work of digital therapeutics developers.
WHY IT MATTERS
The study, called Digital Therapeutics...
Sidekick Health has completed a $20 million (£15.3m) oversubscribed Series A financing round led by Wellington Partners and Asabys Partners, through its fund SAHII, with participation by existing investors Novator and Frumtak Ventures.
The Nordic firm’s fundraising efforts were supported by the EIT Digital Accelerator, a European digital innovation initiative which supports startup and scale-up...
Credit: GluCare Diabetes Center
A specialist clinic that’s claiming to be “the world’s first healthcare provider” to “employ remote continuous data monitoring” for diabetic patients has been officially opened in Dubai.
Following a soft launch in September, GluCare Integrated Diabetes Center – which has been developed in the United Arab Emirates (UAE) with partners in Silicon Valley – offers remote continuous data monitoring as...
